Earnings Feed
Start Free
Coherus Oncology, Inc.·4

Jun 2, 8:29 PM ET

Lanfear Dennis M 4

4 · Coherus Oncology, Inc. · Filed Jun 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Coherus (CHRS) CEO Dennis Lanfear Reprices 3.205M Options

What happened Dennis M. Lanfear, President, CEO and a director of Coherus Oncology (CHRS), participated in a stockholder‑approved option repricing on May 29, 2026. The filing shows matched dispositions to the issuer totaling 3,205,000 option shares and concurrent grants/acquisitions of 3,205,000 repriced options (i.e., old options cancelled and new options issued). The new exercise price for the repriced options is $1.59 per share (approved for options previously priced at or above $5).

Key details

  • Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (filed within the SEC two-business-day window).
  • Total options exchanged: 3,205,000 shares (multiple lots listed; dispositions match acquisitions).
  • New exercise price: $1.59 per share (repricing approved by stockholders).
  • Vesting notes: some options are fully vested/exercisable (F1); other options vest monthly at 1/48th beginning Jan 5, 2023 (F2). Repricing is subject to Lanfear remaining in service through May 29, 2027 (F4).
  • Post‑transaction beneficial ownership was not specified in the provided transaction lines.
  • Transaction type: derivative exchange/repricing — not an open‑market buy or cash sale.

Context This filing documents an option repricing/exchange (old options cancelled and new options issued at a lower strike). For retail investors, this is not an ordinary sale or purchase of stock; it adjusts the economics of previously granted option awards. The filing is factual and timely; it does not, by itself, indicate the insider’s personal trading intent.

Insider Transaction Report

Form 4
Period: 2026-05-29
Coherus Oncology, Inc.CHRS
Lanfear Dennis M
DirectorPresident & CEO
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−200,000→ 0 total
    Exercise: $12.70Exp: 2027-08-06→ Common Stock (200,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−400,000→ 0 total
    Exercise: $10.05Exp: 2028-02-01→ Common Stock (400,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−450,000→ 0 total
    Exercise: $12.37Exp: 2029-01-11→ Common Stock (450,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−500,000→ 0 total
    Exercise: $17.73Exp: 2030-01-10→ Common Stock (500,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−500,000→ 0 total
    Exercise: $18.33Exp: 2031-01-23→ Common Stock (500,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−125,000→ 0 total
    Exercise: $17.60Exp: 2031-02-01→ Common Stock (125,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−402,500→ 0 total
    Exercise: $15.94Exp: 2032-01-04→ Common Stock (402,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F2]
    2026-05-29−402,500→ 0 total
    Exercise: $10.37Exp: 2033-01-05→ Common Stock (402,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F3][F1]
    2026-05-29−225,000→ 0 total
    Exercise: $5.44Exp: 2033-06-13→ Common Stock (225,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+200,000→ 200,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (200,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+400,000→ 400,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (400,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+450,000→ 450,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (450,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+500,000→ 500,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (500,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+500,000→ 500,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (500,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+125,000→ 125,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (125,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+402,500→ 402,500 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (402,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F2]
    2026-05-29+402,500→ 402,500 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (402,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F4][F3][F1]
    2026-05-29+225,000→ 225,000 total
    Exercise: $1.59Exp: 2036-05-29→ Common Stock (225,000 underlying)
Footnotes (4)
  • [F1]The option is fully vested and exercisable.
  • [F2]The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
  • [F3]On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
  • [F4]On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear|2026-06-02

Documents

1 file
  • 4
    tm2616725-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT